Shares of Emergent Biosolutions Inc. (NYSE:EBS) dropped 8.3% during mid-day trading on Monday . The company traded as low as $30.28 and last traded at $30.62, with a volume of 369,111 shares trading hands. The stock had previously closed at $33.39.

EBS has been the subject of a number of research reports. Chardan Capital initiated coverage on Emergent Biosolutions in a report on Friday, April 15th. They issued a “buy” rating and a $47.00 price target for the company. Cowen and Company reiterated a “buy” rating on shares of Emergent Biosolutions in a report on Sunday, April 17th. Zacks Investment Research lowered Emergent Biosolutions from a “strong-buy” rating to a “hold” rating in a report on Monday, May 2nd. Wells Fargo & Co. reiterated a “buy” rating on shares of Emergent Biosolutions in a report on Wednesday, June 22nd. Finally, Singular Research lowered their price target on Emergent Biosolutions from $44.00 to $40.00 and set a “buy” rating for the company in a report on Tuesday, June 28th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and three have assigned a buy rating to the company’s stock. The company has an average rating of “Hold” and a consensus target price of $42.75.

The company has a market capitalization of $1.24 billion and a P/E ratio of 16.55. The firm has a 50 day moving average price of $32.98 and a 200-day moving average price of $36.47.

Emergent Biosolutions (NYSE:EBS) last released its quarterly earnings data on Thursday, May 5th. The biopharmaceutical company reported $0.16 EPS for the quarter, beating the Zacks’ consensus estimate of ($0.07) by $0.23. The business earned $111 million during the quarter, compared to analyst estimates of $101.83 million. During the same quarter in the previous year, the company posted ($0.50) EPS. The firm’s revenue was up 74.5% on a year-over-year basis. Equities research analysts forecast that Emergent Biosolutions Inc. will post $1.45 EPS for the current year.

In other news, major shareholder Fuad El-Hibri sold 85,000 shares of the firm’s stock in a transaction that occurred on Wednesday, May 25th. The shares were sold at an average price of $42.52, for a total transaction of $3,614,200.00. Following the completion of the sale, the insider now owns 1,719,073 shares in the company, valued at approximately $73,094,983.96. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director George A. Joulwan sold 4,700 shares of the firm’s stock in a transaction that occurred on Monday, June 6th. The stock was sold at an average price of $44.12, for a total transaction of $207,364.00. Following the sale, the director now owns 20,785 shares of the company’s stock, valued at approximately $917,034.20. The disclosure for this sale can be found here.

Several hedge funds have recently made changes to their positions in EBS. US Bancorp DE increased its stake in shares of Emergent Biosolutions by 6.9% in the fourth quarter. US Bancorp DE now owns 33,169 shares of the biopharmaceutical company’s stock worth $1,327,000 after buying an additional 2,152 shares in the last quarter. Rhumbline Advisers increased its stake in shares of Emergent Biosolutions by 6.4% in the fourth quarter. Rhumbline Advisers now owns 41,899 shares of the biopharmaceutical company’s stock worth $1,676,000 after buying an additional 2,505 shares in the last quarter. Deere & Co. increased its stake in shares of Emergent Biosolutions by 1.7% in the fourth quarter. Deere & Co. now owns 52,200 shares of the biopharmaceutical company’s stock worth $2,089,000 after buying an additional 888 shares in the last quarter. California State Teachers Retirement System increased its stake in shares of Emergent Biosolutions by 1.6% in the fourth quarter. California State Teachers Retirement System now owns 56,223 shares of the biopharmaceutical company’s stock worth $2,249,000 after buying an additional 885 shares in the last quarter. Finally, Cornerstone Capital Management Holdings LLC. increased its stake in shares of Emergent Biosolutions by 5.9% in the fourth quarter. Cornerstone Capital Management Holdings LLC. now owns 57,927 shares of the biopharmaceutical company’s stock worth $2,317,000 after buying an additional 3,227 shares in the last quarter.

Emergent BioSolutions Inc is a biopharmaceutical company that offers specialized products to healthcare providers and governments to address medical needs and emerging health threats. The Company develops, manufactures and delivers a portfolio of medical countermeasures primarily for government agencies in the areas of biological and chemical threats and emerging infectious diseases (EID).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.